Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precancerous Conditions 3Lung Neoplasms 3Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 45Prednisone 31N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29Vincristine 28Doxorubicin 27Etoposide 22romidepsin 20Gemcitabine 18Lenalidomide 1610-propargyl-10-deazaaminopterin 16fludarabine phosphate 15Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 13Azacitidine 13Mycophenolic Acid 12Dexamethasone 10Cyclosporine 10Bortezomib 10Alemtuzumab 10Rituximab 8fludarabine 7belinostat 7Methotrexate 6Cytarabine 6Busulfan 6Bendamustine Hydrochloride 6pembrolizumab 5denileukin diftitox 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Comparative Genomic Hybridization × Clear all
NCT01336933 2023-09-22

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

University of Nebraska

Phase 2 Completed
34 enrolled 12 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡